Sun Pharmaceutical Industries Ltd, leading specialty generics company, will acquire Organon at $14 per share in an all-cash transaction, valuing the company at an enterprise value of $11.75 billion, funded through internal accruals and borrowings.
The transaction will be executed through a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the merger. The deal is expected to close in early 2027, subject to regulatory approvals and Organon stockholder approval.
Strategic scale-up
Upon completion, Sun Pharma will position itself among the top 25 global pharmaceutical companies, with combined revenues of about $12.4 billion. The combined entity is expected to strengthen its presence in established brands and branded generics, while increasing the share of Innovative Medicines to about 27% of revenue.
The acquisition will also make Sun Pharma a top three player globally in women’s health and the seventh-largest biosimilars company, with a commercial footprint spanning 150 countries, including 18 key markets each generating over $100 million in revenue.
Management commentary
Sun Pharma Executive Chairman Dilip Shanghvi said: “Organon’s portfolio, capabilities and global reach are highly complementary to our own. Bringing the two organisations together can create a stronger and more diversified platform.”
Sun Pharma Managing Director Kirti Ganorkar said: “Immediate priorities will be business continuity, disciplined integration and responsible value creation. There is strong potential to leverage Organon’s talent pool, alongside revenue synergies over the coming years.”
Organon Executive Chair Carrie Cox said: “Sun Pharma is well positioned to support Organon’s businesses, employees and patients globally, and to further advance the commitment to delivering impactful medicines and solutions.”
Organon profile
New Jersey headquartered Organon is a global healthcare company formed as a spin-off from Merck & Co. in 2021 and has a portfolio of more than 70 products across women’s health and general medicines. It operates six manufacturing facilities across the European Union and emerging markets.
For the year ended December 2025, Organon reported revenue of $6.2 billion and adjusted EBITDA of $1.9 billion. It had total debt of $8.6 billion and a cash balance of $574 million.
Organon also recently completed a product divestiture, receiving an upfront payment of $440 million, with net proceeds expected to augment its cash position as of March 2026.